Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab monotherapy and gut microbiome correlation in advanced urothelial carcinoma
ChiCTR2300068570Phase 2Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in transitional cell carcinoma (TCC), sponsored by Changhai Hospital. Primary endpoints: Objective response rate, Disease control rate and 4 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2300068570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068570.